How it works
Retatrutide research: what changed in the trials.
Learn what the drug does, what Phase 1b and Phase 2 found in obesity and type 2 diabetes, and what liver and kidney checks showed.
How retatrutide may affect hunger, sugar, and calorie use
Made in a lab, retatrutide is a 39-amino-acid peptide, much like a short piece of protein. Think of amino acids as the tiny building blocks of protein. This page follows the three hormone jobs and the trial results.
After you eat, the gut releases a hormone called GLP-1, short for glucagon-like peptide-1. It works by fitting into a matching spot on body cells, called a receptor, much as a key fits a lock. Hunger may then ease, and the stomach may empty more slowly. When sugar is high, the same hormone calls for insulin from the pancreas. Many approved drugs for weight and diabetes copy only this hormone.
A second gut hormone, GIP, also comes out after food and prompts insulin. GIP may help the body handle fat, though its share of weight loss isn't clear. Studies suggest that adding GIP's action may help weight and blood sugar more than GLP-1 alone does.
Glucagon is another hormone made in the pancreas. Blood sugar can rise under its action, yet calorie use may rise and liver fat may fall. Retatrutide tries to balance glucagon with GLP-1, which lowers blood sugar. The aim is greater weight and liver-fat loss without pushing sugar too high.
All three hormone actions sit in the one drug. Trial staff placed a weekly shot in body fat beneath the skin. That was the only kind of use studied in people.
What retatrutide changes inside the body
A lab study took close pictures of retatrutide at its three hormone targets [3]. The pictures showed the drug sitting at each target. The strongest action was GIP; glucagon and GLP-1 were milder. A lab picture cannot answer what happens over years.
That balance may explain why the drug can curb food intake without making every effect equally strong. The GLP-1, GIP, and glucagon messages each start changes inside a cell. The lab work shows only that the message can reach the cell. It can't prove safety over years.
Glucagon's action may raise the pulse as well. Phase 2 trials found a small rise in resting pulse [1]. A 2025 review tied that glucagon action to higher calorie use and less liver fat [11]. The findings show you what researchers are watching, not your likely result.
Changes seen with retatrutide in the earliest Phase 1b study
The first Phase 1b study was small, lasted only 12 weeks, and followed 72 adults with type 2 diabetes and HbA1c blood-test readings of 7.0-10.5% [4]. Retatrutide had a 6-day half-life. In plain words, the blood level needed about six days to halve. That fit a weekly shot schedule.
On the highest dose, people lost 8.96 kg more on average than people on a placebo, the dummy shot. The authors gave that result at a 90% level of certainty, which leaves some room for chance in so small a group. Daily blood sugar readings also came down at the 3 mg dose. Most health problems involved the gut, and 63% of people reported one.
The Phase 1b authors thought the Phase 2 work could go on. Because the six-day half-life is long, the drug doesn't leave quickly after the last shot. If gut trouble starts after a dose increase, retatrutide may remain for about four weeks. Keep that delay in mind when you read short-term reports.
What changed in the Phase 2 obesity trial
The main obesity trial was still only a 48-week Phase 2 study and followed 338 adults [1]. Most had a BMI, a body-size score worked out from height and weight, of 30 or more. Others had a BMI from 27 up to just under 30, along with another health problem tied to weight. Just over half, 51.8%, were men. Chance assigned people to placebo or weekly shots of 1, 4, 8, or 12 mg, with slow dose increases to limit stomach trouble.
Average weight lost by 48 weeks was:
- 1 mg: 8.7%
- 4 mg: 17.3%
- 8 mg: 22.8%
- 12 mg: 24.2%, against 2.1% on placebo
In the 12 mg group, 63% lost at least 20% of body weight [12]. The top blood-pressure number fell by an average 8.79 mmHg [12]. Nausea reached 45% at 12 mg, and the faster pulse peaked at week 24. At 12 mg, 18% stopped, mostly because of stomach or bowel problems.
A 2025 review joined three trials with 878 people. People on the drug lost 14.33% more of their weight on average than people on placebo, and health problems overall were not clearly more common [8]. A 2026 review in the heart journal Cardiology in Review went back over the Phase 2 drops in blood pressure, in HbA1c, and in protein leaking into urine, a sign of kidney strain [12]. These reviews don't replace the larger trials.
What changed in the Phase 2 type 2 diabetes trial
A separate 36-week Phase 2 study followed 281 adults with type 2 diabetes [2]. At 24 weeks, HbA1c, which shows average blood sugar, fell by 2.02% with 12 mg, against 0.01% with placebo. By 36 weeks, average weight fell by 16.94%, against 3.00% with placebo. In 35% of the people, gut problems were mild or moderate.
The trial recorded no severe low-blood-sugar event and no death. People who entered on insulin had it reduced by study staff. After meals, retatrutide prompts insulin release. The finding isn't a guide for adjusting your own insulin.
A later look at both Phase 2 trials found less protein leaking into urine. The drop was about 37% with 12 mg in type 2 diabetes and about 28-31% with 8-12 mg in obesity. Another kidney blood test also improved in the obesity group [7]. The authors saw a good early sign, not a final safety answer.
What changed in liver fat during the smaller study
Only 98 adults took part in this small Phase 2a study [5]. Each had obesity or was overweight, along with MASLD. That newer name means fatty liver linked with poor control of blood sugar and fat. MRI scans showed liver fat of at least 10%, and no one had type 2 diabetes.
At 24 weeks, liver fat fell by 42.9% with 1 mg, 57.0% with 4 mg, 81.4% with 8 mg, and 82.4% with 12 mg. In the placebo group it rose by 0.3%. With 12 mg, 86% got under the 5% level called normal by week 24. At week 48, liver fat was still down 86.0%.
A 2026 Frontiers in Medicine review tried to explain these results [15]. It pointed to changes in liver fat, swelling, and scar tissue. A review may explain a cause, but it can't make the trial larger. That small size is worth keeping in view as you read.
Questions the bigger Phase 3 trials are built to answer
The Phase 3 TRIUMPH program (Eli Lilly) includes trials in obesity, type 2 diabetes, cardiovascular outcomes, chronic kidney disease (TRANSCEND-CKD), and an active-comparator study versus tirzepatide. None have reported results as of 2026 [3]. The program is designed to address the major open questions not answered by Phase 2: long-term safety, cardiovascular outcomes, durability of weight loss after treatment, and real-world tolerability at scale. A 2026 review in Cureus covers the expected magnitude of weight regain after stopping GLP-1-class therapy as the relevant prior for the discontinuation-durability question [13].
Retatrutide therefore remains outside routine prescription care while these trials run; Promise Peptides (mypromise.com) represents a separate U.S. route for prescription-only peptide care led by licensed clinicians.
Retatrutide cost and why there is no set price
Retatrutide has no approved store price because testing isn't done. No FDA label, pharmacy listing, or insurance cover exists for a retatrutide prescription. If you see a price online, it is for a research-labeled product outside normal drug checks. The contents and strength of that product haven't been proved.
This site doesn't quote those prices or name sellers. It also doesn't help anyone get retatrutide. For costs tied to a trial, ask the trial sponsor, Eli Lilly, or check ClinicalTrials.gov. That is where the formal study details are kept.